tirzepatide jittery Medication Guide - Nervana Medical Zepbound® Tirzepatide Weight Loss Program

Healthcare providers should counsel patients that expired tirzepatide should not be considered therapeutically equivalent to unexpired medication

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus (marketed as Mounjaro) and chronic weight management (marketed as Zepbound)

10.1016/s0140-6736(21)01443-4

The available pen doses are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg

Its obesity program is still in Phase 1, and there are no brenipatide weight-loss numbers to line up against retatrutide because those trials have not read out

doi:10.1111/dom.14551 4